Last reviewed · How we verify
Neuromodulators
Neuromodulators is a Small molecule drug developed by Capital Medical University. It is currently in Phase 2 development. Also known as: Flupentixol and Melitracen, Citalopram.
-
Baseline phase 2 → approval rate
+15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas). -
CNS / neurology attrition
-3.0pp
CNS drugs have historically high Phase 3 failure rates (notably in Alzheimer disease + major depression).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2031–2034 | — |
| EMA | EU | 2032–2035 | +0.7 yr |
| MHRA | GB | 2032–2035 | +0.7 yr |
| Health Canada | CA | 2032–2036 | +0.9 yr |
| TGA | AU | 2032–2036 | +1.2 yr |
| PMDA | JP | 2032–2036 | +1.5 yr |
| NMPA | CN | 2033–2037 | +2.3 yr |
| MFDS | KR | 2032–2036 | +1.4 yr |
| CDSCO | IN | 2032–2037 | +1.8 yr |
| ANVISA | BR | 2033–2037 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | Neuromodulators |
|---|---|
| Also known as | Flupentixol and Melitracen, Citalopram |
| Sponsor | Capital Medical University |
| Modality | Small molecule |
| Therapeutic area | Neuroscience |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Comparative Effects of Functional Electrical Stimulation and Mirror Therapy for Foot Clearance Among Patients With Sub-acute Stroke (NA)
- Duloxetine in Inflammatory Bowel Diseases (PHASE2)
- An Innovative Intervention for OUD Treatment (PHASE2, PHASE3)
- Exercise and Neuromodulation in Fibromyalgia (NA)
- Novel Pilot Study to Treat Symptoms of IBS With Diarrhea Using Combination Therapy of a Low-FODMAP Diet and a Neuromodulator (EARLY_PHASE1)
- A 2x2 Factorial, Randomized, Open-label Trial to Evaluate Neuromodulators and Cough Control Therapy in Patients With Refractory or Unexplained Chronic Cough (PHASE4)
- Efficacy of Gut-Brain Neuromodulators in the Treatment of Gastroesophageal Reflux Disease (NA)
- Evaluating the Safety and Efficacy of Duloxetine in the Prevention of Post Endoscopic Retrograde Cholangiopancreatography Pancreatitis (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Neuromodulators CI brief — competitive landscape report
- Neuromodulators updates RSS · CI watch RSS
- Capital Medical University portfolio CI
Frequently asked questions about Neuromodulators
What is Neuromodulators?
Who makes Neuromodulators?
Is Neuromodulators also known as anything else?
What development phase is Neuromodulators in?
Related
- Manufacturer: Capital Medical University — full pipeline
- Therapeutic area: All drugs in Neuroscience
- Also known as: Flupentixol and Melitracen, Citalopram
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing